Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Level 2 - randomized trial
Individual randomized, double-blind, placebo-controlled clinical trial
PubMed 34937145 · doi:10.1056/NEJMoa2116846
What was done
A randomized, double-blind, placebo-controlled trial evaluated 562 nonhospitalized patients with confirmed Covid-19 within 7 days of symptom onset who had at least one risk factor for progression (such as age ≥60 years, obesity, or diabetes). Participants were assigned to receive a 3-day course of intravenous remdesivir (200 mg on day 1, 100 mg on days 2 and 3; n = 279) or matching placebo (n = 283). The primary efficacy endpoint was a composite of Covid-19-related hospitalization or all-cause death by day 28. Safety was assessed via adverse event reporting.
What was found
Covid-19-related hospitalization or death occurred in 2 of 279 patients (0.7%) in the remdesivir group compared to 15 of 283 patients (5.3%) in the placebo group (hazard ratio, 0.13; 95% CI, 0.03 to 0.59; P = 0.008), representing an 87% relative risk reduction. Medically attended visits for Covid-19 occurred in 1.6% (4 of 246) of remdesivir recipients versus 8.3% (21 of 252) of placebo recipients (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). Zero patients died by day 28 in either group. Adverse events occurred in 42.3% of the remdesivir cohort and 46.3% of the placebo cohort.
Why it matters
This study demonstrates that early outpatient administration of remdesivir substantially prevents progression to severe disease and hospitalization in symptomatic individuals with baseline risk factors.
Limits
The primary composite endpoint was driven entirely by hospitalizations, as no deaths occurred in either arm by day 28. The absolute number of primary outcome events was low (17 total events across 562 participants), yielding wide confidence intervals. Delivering a 3-day consecutive intravenous infusion presents substantial logistical challenges for outpatient care compared to oral antivirals. Vaccination status and variant-specific efficacy were not detailed in the abstract.
Cited by
- supports Remdesivir demonstrated greater efficacy early in the course of COVID-19 compared to late-stage disease in patients on mechanical ventilators.